170 related articles for article (PubMed ID: 19744014)
1. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
Small DS; Wrishko RE; Ernest CS; Ni L; Winters KJ; Farid NA; Li YG; Brandt JT; Salazar DE; Borel AG; Kles KA; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):585-94. PubMed ID: 19744014
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
[TBL] [Abstract][Full Text] [Related]
3. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
4. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
[TBL] [Abstract][Full Text] [Related]
5. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
Farid NA; Jakubowski JA; Payne CD; Li YG; Jin Y; Ernest II CS; Winters KJ; Brandt JT; Salazar DE; Small DS
Curr Med Res Opin; 2009 Aug; 25(8):1821-9. PubMed ID: 19530977
[TBL] [Abstract][Full Text] [Related]
6. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
8. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
[TBL] [Abstract][Full Text] [Related]
9. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
Small DS; Kothare P; Yuen E; Lachno DR; Li YG; Winters KJ; Farid NA; Ni L; Jakubowski JA; Salazar DE; Thieu VT; Payne CD
Eur J Clin Pharmacol; 2010 Feb; 66(2):127-35. PubMed ID: 19888568
[TBL] [Abstract][Full Text] [Related]
12. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.
Jakubowski JA; Payne CD; Brandt JT; Weerakkody GJ; Farid NA; Small DS; Naganuma H; Li GY; Winters KJ
J Cardiovasc Pharmacol; 2006 Mar; 47(3):377-84. PubMed ID: 16633079
[TBL] [Abstract][Full Text] [Related]
13. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
Weerakkody GJ; Jakubowski JA; Brandt JT; Farid NA; Payne CD; Zhu J; Warner MR; Naganuma H; Winters KJ
Am J Cardiol; 2007 Jul; 100(2):331-6. PubMed ID: 17631093
[TBL] [Abstract][Full Text] [Related]
14. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
Small DS; Wrishko RE; Ernest CS; Ni L; Winters KJ; Farid NA; Li YG; Salazar DE; Payne CD
Drugs Aging; 2009; 26(9):781-90. PubMed ID: 19728751
[TBL] [Abstract][Full Text] [Related]
15. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Payne CD; Li YG; Brandt JT; Jakubowski JA; Small DS; Farid NA; Salazar DE; Winters KJ
Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Li YG; Ni L; Brandt JT; Small DS; Payne CD; Ernest CS; Rohatagi S; Farid NA; Jakubowski JA; Winters KJ
Platelets; 2009 Aug; 20(5):316-27. PubMed ID: 19637095
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.
Small DS; Li YG; Ernest CS; April JH; Farid NA; Payne CD; Winters KJ; Rohatagi S; Ni L
J Clin Pharmacol; 2011 Mar; 51(3):321-32. PubMed ID: 20410452
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
Wrishko RE; Ernest CS; Small DS; Li YG; Weerakkody GJ; Riesmeyer JR; Macias WL; Rohatagi S; Salazar DE; Antman EM; Wiviott SD; Braunwald E; Ni L
J Clin Pharmacol; 2009 Aug; 49(8):984-98. PubMed ID: 19546250
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
20. Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis.
Ernest CS; Heathman MA; Wrishko RE
J Clin Pharmacol; 2009 Aug; 49(8):973-83. PubMed ID: 19602721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
